The themes Edesa Biotech is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Built from Edesa Biotech, Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
$1.94-6.7%Nov 13 close
Next earnings: December 11, 2026
Figures through June 30, 2026, from the 10-Q filed August 13, 2026
Not rated
The band under the price shows the grade on each date, built only from filings that were public by then.
Showing 2 of 31 quarters of Edesa Biotech, Inc.’s grade history. The other 29 go back to December 2016.